Hervé Hoppenot, Incyte CEO
October 3, 2022 07:27 AM EDT
Deals

In­cyte pays out $70M to get hands on Medicxi-backed vi­tili­go biotech

Paul Schloesser

Associate Editor

The M&A wheels keep on turn­ing in biotech — and this time it’s In­cyte that gets to do the deal­mak­ing.

The Delaware biotech put out word …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

As the XBI suf­fers, Q1 shows a few com­fort­ing signs of un­der­ly­ing sta­bil­i­ty

Roche promis­es $50B in­vest­ment in the US as phar­ma tar­iffs inch clos­er

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

As­traZeneca, Dai­ichi eye first-line breast can­cer mar­ket af­ter En­her­tu's ear­ly Phase 3 win

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times